InstaDeep develops artificial intelligence-enabled decision-making systems for enterprises. It provides predictive analytics solutions for enterprise clients, particularly in the biomedical, mobility, and transportation spaces and offers and its product line includes DeepChain, DeepPack, and DeepPCB. InstaDeep was formerly known as Digital Ink Group. It was founded in 2014 and is based in London, United Kingdom. In January 2023, InstaDeep was acquired by BioNTech.
InstaDeep's Product Videos
ESPs containing InstaDeep
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The generative AI — protein & drug design market offers solutions to the challenges faced by traditional drug development processes, which are inefficient and high-risk. By using generative AI, companies can significantly reduce the time and cost of drug discovery, accelerate the development cycle to design next-generation therapeutics and vaccines, and engineer proteins with fewer experiments. Th…
InstaDeep's Products & Differentiators
AI-Accelerated Drug Design
Research containing InstaDeep
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned InstaDeep in 4 CB Insights research briefs, most recently on Jun 20, 2023.
Expert Collections containing InstaDeep
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
InstaDeep is included in 3 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The winners of the 4th annual CB Insights AI 100.
Companies working on generative AI applications and infrastructure.
InstaDeep has filed 5 patents.
Artificial neural networks, Rotating disc computer storage media, Machine learning, Data mining, Classification algorithms
Artificial neural networks, Rotating disc computer storage media, Machine learning, Data mining, Classification algorithms
Latest InstaDeep News
Nov 28, 2023
Tech.eu Tech.eu Insights creates insight and guides strategies with its comprehensive content and reports. Browse popular Insights content. European startup funding down more than half at $45B in 2023 While 2023's $45 billion is down more than half from 2022, historic trends reveal a pattern of long-term growth and stability across the European tech ecosystem. Released today, Atomico's State of European Tech 2023 report highlights that total capital investment into the European tech ecosystem in 2023 is on track to reach around $45 billion, representing a decrease of more than half (55 percent) from the record year of 2021 (when the ecosystem reached over $100 billion for the first time), and around 38 percent compared to 2022 (with a total of $82 billion). The report also states that this decline is unsurprising, as there were some shifts in the broader macroeconomic landscape. Thus, there happens to be the dual effect of many later-stage companies delaying fundraising, but also materially slower deployment pacing by investors which led to a decline of the growth stage investment rounds. But, even though there has been a decline in the last two years, with the total capital invested, 2023 is on track to the third-largest year on record. Source: Atomico Europe is the only region that records growth in investments (18 percent) compared to 2020 The report states that the early-stage investments are still stable despite the turbulence in the investment volume since 2021. But, if we exclude the period from Q1 2021 to Q2 2022, we can see the constant long-term growth investment in the European tech ecosystem which might give us the confirmation that even with the lower numbers, the ecosystem is on the right track. Compared with other regions, Europe is the only region that records a growth (18 percent) compared to 2020. Source: Atomico Foreign investment retreats The number of active investors in European tech companies has steadily increased over the past decade. In the period from 2021 and the first half of 2022, these investments were largely fueled by investors from outside the region, especially from North America. Although there's been a retreat in 2023 due to reduced participation from non-European investors, the overall base of active investors remains more than double a decade ago which signals a commitment to supporting the European tech ecosystem through market cycles. Venture debt Venture debt funding in European tech has decreased in absolute terms from the highs of 2021 and 2022. Still, it aligns with the overall trend in equity investment volumes. The projected total debt financing for 2023 is around $1.5 billion, constituting approximately 3.4 percent of the total equity investment capital over the same period. These numbers indicate a decline from the peak of $4.4 billion in 2021 but remain consistent with 2019 or 2020 levels. Women-led companies There is some progress when it comes to the share of capital invested by women-led companies compared to a year before, but, still not enough. As stated in the report, in the funding landscape for women-led companies, there is a notable drop-off in shares as companies progress beyond the Pre-Seed stage, with women-only teams capturing a mere 2.2 percent of funding in Series B and beyond. This underscores unequal expectations for male and female founders, highlighting the need for more equal opportunities across all stages of company maturity. UK market share slipping The decline in capital investment in private European tech companies is widespread, with significant year-on-year decreases in every major European country between 2022 and 2023. Although still in the leading position, when it comes to capital invested, the UK has been gradually losing market share on the European level. In terms of the number of tech startups founded each year, approximately a quarter of all new companies in Europe come from the UK. On the other side, the fastest-rising country in terms of the share of new tech startups created each year is France, which has seen its share increase from 18 percent in 2019 to 22 percent in 2023. Speaking of the startup concentration, smaller countries like Estonia emerge as leaders highlighting the importance of considering population size to benchmark the true level of startup activity. Estonia stands atop One of the clearest indicators of the tech entrepreneurship and diversity of Europe's startup ecosystems is the number of countries that have produced a breakout, billion-dollar company. Today, a total of 356 companies are currently valued in excess of $1 billion, and they have been started and scaled from 29 countries and 136 cities. Source: Atomico From a geopolitical point of view, Estonia consistently stands out as the top performer in billion-dollar company density, boasting 4.5 companies valued at over $1 billion for every one million inhabitants, a distinction it has maintained for several years. Slicing the pie Even though there are differences in the distribution of ecosystem values within the region, in the past five years, it has stayed quite stable. Three regions (UK and Ireland, France and Benelux, and DACH) capture 76 percent of the combined ecosystem value in 2023, underscoring the prevailing disparities across different parts of Europe. However, the rest of Europe has done some catching up, increasing their share of the pie from 17 percent in 2019 to 24 percent in 2023. The dominance of the climatech Almost 27 percent of all capital invested in European tech in 2023 comes from the Carbon and Energy sector, doubling its share of investment since 2021. This shows the increase of the capital investment behind green transitions and the slowdown of fintech investment volumes since its peak in 2021. This dominance of the Carbon and Energy sector is present across almost every major European country, while it's the highest in the Nordics, representing 48 percent of all capital invested in Norway and 44 percent in Sweden. However, Health is the single largest investment sector of 2023 in Denmark and Switzerland (with 39 percent and 38 percent of total capital invested, respectively). Source: Atomico Hard on hardware, soft on software A large share gain of capital investment this year went to Enabling Technologies (which includes core technologies such as AI Infrastructure, Quantum Computing, and Semiconductors). On the contrary, the Finance and Insurance sector accounted for the largest overall year-on-year declines in the share of investment, followed by the Software sector, which saw a drop of eight percentage points in its 2023 share of investment versus. 2022 levels. Atomico’s 258-page State of European Tech 2023 report is now available and goes on to outline a number of additional topics, including exclusive video interviews with OpenAI CTO Mira Murati, the founders of Aleph Alpha, Deepl, Mistral, Corti , Kheiron Medical , and Instadeep and can be accessed at stateofeuropeantech.com . You might also want to check out our additional coverage of the report at:
InstaDeep Frequently Asked Questions (FAQ)
When was InstaDeep founded?
InstaDeep was founded in 2014.
Where is InstaDeep's headquarters?
InstaDeep's headquarters is located at 5 Merchant Square, London.
What is InstaDeep's latest funding round?
InstaDeep's latest funding round is Incubator/Accelerator - VII.
How much did InstaDeep raise?
InstaDeep raised a total of $113.65M.
Who are the investors of InstaDeep?
Investors of InstaDeep include African Unicorns, BioNTech, NVIDIA Inception Program, DB Digital Ventures, Alpha Intelligence Capital and 12 more.
Who are InstaDeep's competitors?
Competitors of InstaDeep include Cradle, Valence, Insilico Medicine, Aqemia, Endel and 7 more.
What products does InstaDeep offer?
InstaDeep's products include DeepChain.
Who are InstaDeep's customers?
Customers of InstaDeep include BioNTech.
Compare InstaDeep to Competitors
Cradle is a company focused on the intersection of biology and artificial intelligence, operating within the biotechnology industry. The company offers a platform that aids biologists in designing improved proteins swiftly, utilizing advanced prediction algorithms and AI design suggestions. Cradle primarily serves the biotechnology sector. It was founded in 2021 and is based in Delft, Netherlands.
Aqemia offers drug discovery software predicting the affinity between drug candidates and therapeutic targets responsible for diseases. It uses quantum and statistical mechanics algorithms fuelling a generative artificial intelligence (AI) to design drug candidates. The company was founded in 2019 and is based in Paris, France.
Insilico Medicine operates as a clinical-stage biotechnology company operating in pharmaceutical research and development. It offers services that include novel target discovery, generation of molecular structures with desired properties, and clinical trial analysis, enabled by advanced machine learning techniques. Its services primarily cater to the healthcare industry, with a particular emphasis on the discovery and development of innovative drugs for a range of conditions including cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It was founded in 2014 and is based in New Territories, Hong Kong.
Biomatter Designs is a company focused on the engineering of proteins, operating within the health and sustainable manufacturing sectors. The company's main service involves the creation and design of proteins for use in health applications and sustainable manufacturing processes. It was founded in 2018 and is based in Vilnius, Lithuania.
Variational AI is a Vancouver, British Colombia-based company leveraging artificial intelligence to help develop new small molecule drugs.
YDS Pharmatech is a company focused on drug discovery in the pharmaceutical industry. The company offers a platform for the design of new drug candidates, utilizing structure-based de novo drug design and evolutionary AI to accelerate the drug discovery process. YDS Pharmatech primarily serves the pharmaceutical industry. It was founded in 2020 and is based in Albany, New York.